

**Kyriakos E. Kypreos**

Detailed Curriculum Vitae  
and  
Description of published work

May 19, 2014

## ΠΕΡΙΕΧΟΜΕΝΑ

PART A.....	<b>Error! Bookmark not defined.</b>
1. PERSONAL DETAILS .....	4
2. EDUCATION.....	5
3. POSTGRADUATE EDUCATION-INTERNATIONAL EXPERIENCE.....	6
3.1. POSTGRADUATE EDUCATION.....	6
3.2. Visiting professor.....	7
4. ACADEMIC POSITION.....	7
5. EXPERIENCE IN PHARMACEUTICAL INDUSTRY.....	7
6. BRIEF PRESENTATION OF RESEARCH INTERESTS .....	8
Current members of my research team.....	9
Past members of my research team –Ph.D, master, and graduate theses.....	10
Postdoctoral researchers.....	10
Doctorate students .....	10
Master Students .....	11
Undergraduate students.....	12
7. RESEARCH GRANTS .....	14
8. HONORS-AWARDS.....	15
9. INVITED LECTURES.....	16
10. PATENTS.....	18
11. TEACHING EXPERIENCE.....	19
12. PARTICIPATION IN THESIS COMMITTEES .....	20
13. REVIEWER FOR INTERNATIONAL FUNDING AGENCIES.....	24
14. PARTICIPATION IN GREEK AND INTERNATIONAL RESEARCH NETWORKS.....	25
15. PARTICIPATION IN THE EDITORIAL BOARD OF PEER-REVIEWED INTERNATIONAL JOURNALS .....	26
16. REVIEWER IN INTERNATIONAL PEER-REVIEWED JOURNALS .....	27
17. ADMINISTRATIVE POSITIONS.....	28
18. COMMUNITY SERVICE.....	29
19. PUBLICATIONS .....	30

20. PEER-REVIEWED ORAL PRESENTATIONS IN SCIENTIFIC CONFERENCES.....	37
21. CITATIONS, IMPACT FACTORS.....	41
22. PRESENTATION OF MY WORK IN INTERNATIONAL WEBSITES.....	41
23. SOCIETIES - MEMBERSHIPS .....	42

## 1. PERSONAL DETAILS

FIRST NAME: Kyriakos  
LAST NAME: Kypreos  
MIDDLE NAME: Elias  
DATE OF BIRTH: Augsut 4, 1970  
MILITARY DUTY: Completed  
MARITAL STATUS: Married  
WORK ADDRESS: University of Patras  
Department of Medicine  
Pharmacology laboratory  
Panepistimiupolis  
Rio Achaias, TK. 26500  
Tel: +302610969120  
Email: [kkypreos@med.upatras.gr](mailto:kkypreos@med.upatras.gr)

## 2. EDUCATION

### 2.1. HIGH SCHOOL

**General highschool of Ialyssos, Rhodes**

Graduated on June 1988. Graduation mark: Excellent, 18 <sup>5</sup>/<sub>10</sub>

### 2.2. GRADUATE STUDIES

**University of Crete Department of Chemistry**

September 1988-July 1992

Graduation mark «Excellent, 8,53»

*1<sup>st</sup> Practical exercise:*

June 1991-December 1991, University of Crete, Department of Chemistry, Inorganic Chemistry laboratory. Supervisor, Assist. Prof. A. Koutsolelos.

*2<sup>n</sup> Practical exercise:*

January 1992-June 1992, University of Crete, Department of Medicine, Biochemistry laboratory. Supervisor: Prof. V. I. Zannis

During my undergraduate studies I received the “Svoronos” student achievement award by the Department of Chemistry

### 2.3. Graduate studies

**Boston University School of Medicine**

September 1992-May 1998

Thesis advisor: Professor Gail E. Sonenshein

Thesis title: “Regulation of collagen gene expression by basic Fibroblast growth factor and b-myb in bovine aortic smooth muscle cells”

Degree obtained: Doctor of Philosophy in Biochemistry (Ph.D), Awarded by the Trustees of Boston University on the recommendation of the faculty of Boston University School of Medicine.

During my Ph.D. thesis work I participated in 6 original publications in international peer-reviewed Journals and in two book chapters. For my academic performance in 1997 I received the «*Henry I. Russek Student Achievement Award*» by *Russek Medical Foundation* of Boston.

### **3. POSTGRADUATE EDUCATION-INTERNATIONAL EXPERIENCE**

#### **3.1. POSTGRADUATE EDUCATION**

##### **3.1. 1. Boston University School of Medicine, Boston, U.S.A.**

May 1998-August 2000

Molecular Genetics Unit, Whitaker Cardiovascular Institute

Supervisor: Professor Vassilis I. Zannis

Founding source: NIH-NHLBI postdoctoral Fellow

Laboratory: «*Structure function analysis of human apolipoprotein E for the development of lead biological drugs for the treatment of atherosclerosis and coronary heart disease using novel gene therapy approaches*».

##### **3.2.1. University of Alabama at Birmingham, Gene Therapy Center**

December 1999

Laboratory: Professor dr. David Curiel

Visiting scientist: The aim of the visit was to receive training on adenovirus mediated gene transfer in live animals.

##### **3.3. 1. Leiden University Medical Center, Leiden, The Netherlands**

September 2000-August 2002

Department of human and clinical genetics, Sylvius Laboratory

laboratory: Assoc. Professor Ko Willems van Dijk και Prof.

dr. Louis M. Havekes

Funding source: Marie-Curie Excellence Award

Research topic: «*Development of novel gene therapy approaches for the delivery of apolipoprotein E-based lead biological drugs for atherosclerosis and coronary heart disease*».

##### **3.4. 1. TNO-PG Prevention and Health, Leiden, The Netherlands**

September 2002-August 2004

Department of Pharmaceutical products –Lipidology Unit

Laboratory: Professor dr. Louis M. Havekes

Funding source: EMBO Fellowship Award

Research topic: «*Development of novel gene therapy approaches for the delivery of apolipoprotein E-based lead biological drugs for the treatment of atherosclerosis and coronary heart disease*».

## **3.2. Visiting professor**

### **3.2.1. ICBP-NS, Bucharest, Romania.**

September-October, 2004

Laboratory: Professor dr. Anca Sima.

The aim of my visit was to educate the members of the institute on cutting edge adenovirus mediated gene transfer methodologies

## **4. ACADEMIC POSITION**

**4.1. Professor in Pharmacology-** University of Patras, School of Health Sciences, Department of Medicine (Elected on December 6, 2013).

**4.2. Associate Professor in Pharmacology.** University of Patras, School of Health Sciences, Department of Medicine, May 2008-Present.

**4.3. Assistant Professor in Medicine.** Boston University School of Medicine, Whitaker Cardiovascular Institute, September 2006-May 2008.

**4.4. Instructor in Medicine.** Boston University School of Medicine, Whitaker Cardiovascular Institute, September 2004-August 2006.

**4.5. Senior Research Scientist.** Leiden University Medical Center, September 2004-April 2008.

## **5. EXPERIENCE IN PHARMACEUTICAL INDUSTRY**

### **5.1. KOS-Pharmaceuticals, Miami, FL, USA.**

September 2001-June 2007

Member of the scientific advisory board of the company led by CSO, Dr. Gene Cefali.

### **5.2. Freelance pharmaceutical consulting.**

September 2001-April 2008

Consultant on coronary heart disease prevention strategies for Major pharmaceutical companies

## 6. BRIEF PRESENTATION OF RESEARCH INTERESTS

My scientific work focuses on the role of lipid and lipoprotein transport system in the development of metabolic syndrome. Since the syndrome is a mosaic of various pathological disorders, my research activity focuses on understanding of the contribution of lipoproteins and their protein components to obesity, type II diabetes, dyslipidemia (specifically hypertriglyceridemia and low-dysfunctional HDL), atherosclerosis and coronary heart disease, non-alcoholic fatty liver disease, and metabolic bone disorders, associated with the metabolic syndrome.

The aim of our research is the identification of new pharmacological targets for the development of innovative biological drugs for gene therapy of these disorders. Consequently, the ultimate benefit from our studies is the individualization of gene-based pharmacological intervention based on the genetic profile of the treated patient.

The constantly increasing prevalence of metabolic syndrome worldwide makes the development of new drugs imperative. The causal relationship of obesity and metabolic syndrome with impaired energy balance in the patient, in combination with the pivotal role of the lipoprotein system in the management of blood lipids bring our studies to the forefront of pharmaceutical research. Our research builds on the recently formulated hypothesis by us that stimuli from the lipoprotein transport system engage into a functional cross talk with mechanisms responsible for energy balance and the consequently development of metabolic syndrome.

Our main research directions are:

1. Study the role of components of chylomicron metabolic pathway in obesity and accompanying metabolic disorders.
2. Study the role of components of the HDL metabolic pathway on obesity and accompanying metabolic disorders.
3. Study of qualitative and functional characteristics of HDL associated with atherosclerosis and coronary heart disease in order to individualize diagnosis and treatment.
4. Study of the effect HDL on the viability and functionality of pancreatic beta cells.
5. Study of the functional interaction between components of the lipoprotein transport system with androgen signaling in diet-induced obesity and type II diabetes
6. Study of the effects of HDL and brown adipose tissue on lipopolysaccharide (LPS) induced inflammation

In relation to our work on the pharmacology of HDL, the recent joint update of guidelines of the American Heart Association and the American College of Cardiology

(<http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a>) which abolished cholesterol levels (total, LDL, nonHDL and HDL) and triglycerides, as clinical targets of pharmacological interventions for the



prevention of coronary mortality , constitute confirmation of the importance of our research activities in the last ten years or so. In particular our results support that levels of HDL cholesterol in the blood have questionable value in relation to the calculation of cardiovascular risk and may not be a pharmacological target. Instead our data support that the quality and functionality of lipoprotein HDL as effective pharmacological target.

Our theory about the quality of HDL as a pharmacological target was presented for the first time in a review article published online in late 2009 and in print in early 2010 ([Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 2010 Jan;208\(1\):3-9](#)). This paper is one of the first articles internationally, that openly challenge the importance of HDL cholesterol levels as a marker and pharmacological target. Even to this date and against internationally established doctrine, we are among the few leading research groups highlighting the importance of the functionality of HDL and not the amount of HDL cholesterol in the blood as a risk factor and as a pharmacological target.

As a testimony of these facts, a simple search in pubmed using the search term "HDL quality" returns only 15 articles, mainly after 2010 when the failure of HDL-C raising drugs confirmed our theory that only the quality and functionality of HDL lipoprotein , not the amount of HDL cholesterol in the blood is a pharmacological target [Kypreos KE, Gkizas S, Rallidis LS, Karagiannides I. \(2013\) HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochem Pharmacol. 85\(11\):1575-8](#)). Before 2010 only three research groups worldwide spoke for quality and functionality of HDL rejecting levels of HDL-C, one of them being us.

Thus the elimination of cholesterol levels ( total LDL, nonHDL, HDL) from the AHA / ACC guidelines as indicators of risk for coronary events is in full agreement with our suggestions ( as published from time to time in the literature ) and confirm the current clinical importance of our observations. Our theory that the amount of HDL-C levels are not a meaningful pharmacological target ([Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis. 2010 Jan;208\(1\):3-9](#)) was further confirmed by a recent meta-analysis of more than 100,000 patients in various clinical studies published in the journal THE LANCET. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(12\)60312-2/abstract](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60312-2/abstract) .

#### **Current members of my research team:**

**Eleni A. Karavia.** Postdoctoral fellow.

**Jimmy FP Berbee.** Postdoctoral fellow.

**Peristera-Ioanna Petropoulou.** Ph.D student.

**Katerina Hatziri.** Ph.D student.

**Diogenis Mpatsoulis.** Ph.D student.

**Evangelia Svintzou.** Master student.

**Eva Xapapadaki.** Master student.

Anastasios Natsos, Master student.  
Stathianna Douroumi, Medical Student.  
Aikaterini Konstantinou, Research associate.  
Spyridon Gkizas, Research Associate.  
Christina Kalogeropoulou. Master Student  
Alexander Kokossis, Master student.  
Marilena Karaviraki, Master student.  
Eugenia Papakosta, Master student.

Past members of my research team –Ph.D, master, and graduate theses.

#### Postdoctoral researchers

**Aikaterini Tzortzopoulou (2006-2008)**, Medical Doctor.  
Graduate of Athens University.  
Research topic : «*Role of apolipoprotein E in metabolic syndrome*»  
During her tenor in my lab Dr.Tsotsopoulou participated in one publication :  
Iordanes Karagiannides, Rami Abdou, **Aikaterini Tzortzopoulou**,  
Peter Voshol and Kyriakos E. Kypreos (2008) Apolipoprotein E  
predisposes to obesity and related metabolic dysfunctions in mice.  
*FEBS J*, 275: 4796-809.

#### Doctorate students

**Eleni Karavia (2009-2012)**  
Thesis title: «The components of the lipid and lipoprotein transport system as central modulators in the development of obesity and nonalcoholic fatty liver disease in experimental mouse models»  
The thesis work of Dr. Karavia led to the following publications:

##### *In international peer-reviewed Journals:*

1. Irene-Eva Triantaphyllidou, Eleni Kalyvioti, Eleni A. Karavia, Ioannis Lilis, Kyriakos E. Kypreos, Dionysios J. Papachristou (2012) Perturbations in the HDL metabolic pathway predispose to the development of osteoarthritis in mice following long-term exposure to Western-type diet. **Osteoarthritis Cartilage** (doi:pil: S1063-4584(12)01016-3. 10.1016/j.joca.2012.11.003)
2. Eleni A. Karavia, Dionysios J. Papachristou, Kassiani Liopeta, Irene-Eva Triantafyllidou, Odyssefs Dimitrakopoulos, and Kyriakos E. Kypreos (2012) Apolipoprotein A-I modulates Processes Associated with Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. **Mol Med.** 18(9):901-12. doi: 10.2119/molmed.2012.00113.
3. Eleni A. Karavia, Dionysios J. Papachristou, Ioanna Kotsikogianni, Irene-Eva Triantafyllidou, and Kyriakos E. Kypreos (2012, in press) Lecithin:cholesterol acyltransferase modulates the severity of diet-induced nonalcoholic fatty liver disease in mice. **J. Nutr. Biochem.** DOI: 10.1016/j.jnutbio.2012.02.007.

4. Eleni A. Karavia, Dionysios J. Papachristou, Ioanna Kotsikogianni and Kyriakos E. Kypreos (2011) Deficiency in Apolipoprotein E has a Protective effect on Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. **FEBS J**, **278:3119-29**.
5. Kyriakos E. Kypreos, Iordanes Karagiannides, Elisavet Fotiadou, Eleni A. Karavia, Maria Brinkmeier, Smaragda M. Giakoumi, Eirini Tsobanidi (2009) Mechanisms of Obesity and related pathologies: Apolipoprotein E in the development of obesity. **FEBS J** **276: 5720-8**.

*In books:*

1. Eleni A. Karavia and Kyriakos E. Kypreos (2010) "HDL and cardiovascular disease" in From Vascular Cell Biology to Cardiovascular Medicine (Georgescu A., eds) (ISBN 978-81-7895-503-2).

### **Master Students**

**Evangelia Zvintzou (2011-2013)**, Biologist, graduate of the Biology Department of Aristotelian University of Thessaloniki.

Thesis work: « *Effects of weight loss on HDL particle structure and functionality following malabsorptive bariatric surgery* ».

**Diogenis Mpatsooulis (2009-2012)**

Thesis work: «*Metabolic effects of testosterone deficiency in male mouse models*»

**Angeliki Lampropoulou (2010-2012)**

Thesis work: «*Pharmacokinetic and pharmacodynamics characterization of an apoE form with improved biological functions*»

The work of Ms. Lampropoulou was published in:

Angeliki Lampropoulou, Vassilis I. Zannis, and Kyriakos Kypreos. (2012) Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties.

**Biochemical Pharmacology**, 84(11):1451-8.

doi: 10.1016/j.bcp.2012.09.006. Epub 2012 Sep 14.

**Peristera-Ioanna Petropoulou (2009-2011)**

Thesis work: «*Domains of apolipoprotein E contributing to HDL biogenesis in vivo*»

The work of Ms. Petropoulou was published in:

Peristera A. Petropoulou, Donald L. Gantz, Yanan Wang, Patrick C.N. Rensen, and Kyriakos E. Kypreos (2011). The aminoterminal 1-185 domain of human apolipoprotein E suffices for the de novo biogenesis of apoE-containing HDL. **Atherosclerosis**, **219:116-23**.

**Anthula Kavou (2009-2011)**

Thesis work: «*Qualitative and functional characterization of HDL isolated from young asymptomatic patients*»

The work of Ms. Kavou was published in:

Anthula E. Kavo, Loukianos Rallidis, George C. Sakellaropoulos, Stefan Lehr, Sonja Hartwig, Juergen Eckel, Polixeni Mpozatzi, Panagiota Tsikrika, and Kyriakos E. Kypreos (2012) Qualitative characteristics of HDL particles in young asymptomatic patients of an acute myocardial infarction. *Atherosclerosis*, 220:257-64.

**Elisavet Fotiadou, (2008-2010)**

Thesis work: «*Study of a recombinant apolipoprotein E form with improved biological properties*»

**Rami Abdu, (2004-2006)**

Thesis work: «*Structure function analysis of human apolipoprotein CIII using adenovirus mediated gene transfer*»

Dr. Abdu work is presented in the following publications:

1. Abdulmageed M. Traish, **Rami Abdou**, and Kyriakos E. Kypreos (2009) Androgen deficiency and atherosclerosis: The lipid link. *Vascul Pharmacol.* 51: 303-13.
2. Iordanes Karagiannides, Rami Abdou, **Aikaterini Tzortzopoulou**, Peter Voshol and Kyriakos E. Kypreos (2008) Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. *FEBS J*, 275: 4796-809.

**Robert Feely (2006-2008)**

Thesis Topic: «*The Dark Side of Testosterone Deficiency: Metabolic Syndrome & Erectile Dysfunction*»

**Undergraduate students**

**Marilena Karaviraki (2012), Βιολόγος, Τμήμα Βιολογίας**

Πανεπιστημίου Πατρών

Research topic: «*Role of the endogenous lipogenic genes in the development of apolipoprotein A-I induced nonalcoholic steatohepatitis*»

**Panagiota Tsikrika (2011)**

Research topic: «*Study of apolipoprotein C-I in sufferers of an acute myocardial infarction*»

The work of Ms. Tsikrika was included in the publication:

Anthula E. Kavo, Loukianos Rallidis, George C. Sakellaropoulos, Stefan Lehr, Sonja Hartwig, Juergen Eckel, Polixeni Mpozatzi, Panagiota Tsikrika, and Kyriakos E. Kypreos (2012) Qualitative characteristics of HDL particles in young asymptomatic patients of an acute myocardial infarction. *Atherosclerosis*, 220:257-64.

**Polina Bozatzis (2011)**

Research topic: «*Study of the distribution of apolipoprotein C-III in young sufferers of an acute myocardial infarction*»

The work of Ms. Bozatzis was included in the publication:

Anthula E. Kavo, Loukianos Rallidis, George C. Sakellaropoulos,

Stefan Lehr, Sonja Hartwig, Juergen Eckel, Polixeni Mpozatzi, Panagiota Tsikrika, and Kyriakos E. Kypreos (2012) Qualitative characteristics of HDL particles in young asymptomatic patients of an acute myocardial infarction. **Atherosclerosis**, 220:257-64.

**Panagiota Spanou (2011)**

Research topic: «*Expansion and purification of recombinant adenoviruses expressing the human apolipoprotein E and the receptor related protein RAP*»

## 7. RESEARCH GRANTS

### AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

1. Postdoctoral Fellowship «Siemens» by the Hellenic IKY. This funding supports the work of postdoctoral fellow Dr. Constantinou in our lab. This is a highly competitive award since it is one of the 14 fellowships offered in the thematic area “Health”.
2. GSRT, “Excellence I” research Grants, MetSE, 2012-2015, Principal investigator (Active).
3. GSRT «Supporting Postdoctoral Researchers», InflaHDL, LS4-848, February 2012-January 2015, Principal investigator (active).
4. GSRT «Supporting Postdoctoral Researchers», Lipobesity, LS4-879, May 2012-April 2015, Principal investigator (active).
5. European Research Council, International Reintegration Grant (IRG), July 2010-June 2014, Co-principal investigator (active).
6. University of Patras, Karatheororis Award, January 2009-December 2012, Principal investigator (active).
7. \* European Research Council, International Reintegration Grant (IRG), November 2009-November 2012, Principal investigator (active).

\*Following review of the final progress report of the project (*acronym (metabolicsyndrome, Proj No 219129)*) the review committee concluded that the execution of the project was excellent and the studies achieved all set goals. The review is available upon request.

### PRIOR TO MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

8. American Heart Association, Scientist Development Grant, July 1 2005- June 30 2008, Principal Investigator.
9. NIH/NIA, Type: R01 (HL68216), Co-principal investigator 1/1/2001 - 6/30/2006.
10. NIH/NIA, Type: R01 (HL 48739, Co-principal investigator 2/1/2007 – 1/31/2012 Co-principal Investigator (active).
11. Industrial Grant by KOS Pharma, Miami, FL. 2005-2007 Co-principal Investigator.
12. EMBO Long term fellowship, May 1 2002- August 30 2004.
13. Marie Curie Excellence Grant, September 2000-August 2002.

## 8. HONORS-AWARDS

### AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

1. October 13, 2011. “Dimitris Manios” Award for best oral presentation, Hellenic Society of Orthopedic Surgery and Traumatology.
2. June 26, 2011, Travel Award, 10<sup>th</sup> Meeting of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary.

### PRIOR TO MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

1. May 2002, EMBO Long-Term Fellowship Award, EMBO, Heidelberg.
2. \*April 2002, “Irvine H. Page” First Award Winner, American Heart Association, U.S.A.
3. January 2001, “Marie-Curie Individual Fellowship Research Award” Winner, European Commission for Research and Development, Brussels, European Union.
4. November 2000, “Evans Award”, Evans Medical Foundation, Boston University, Boston, USA.
5. April 1997, “Henry I. Russek” Student Achievement Award, First Prize, Boston, USA.

\* This award is offered annually only to one scientist worldwide in recognition of his/her contribution and potential to excel in cardiovascular research in the future. More details can be found below:

[http://my.americanheart.org/professional/Councils/AwardsandLectures/EarlyCareer/Irvine-H-Page-Young-Investigator-Research-Award\\_UCM\\_322534\\_Article.jsp](http://my.americanheart.org/professional/Councils/AwardsandLectures/EarlyCareer/Irvine-H-Page-Young-Investigator-Research-Award_UCM_322534_Article.jsp)

## 9. INVITED LECTURES

### AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

**September 10-12, 2013**, Biomimetic radicals in membrane lipids, COST action CM1201, Invited speaker, Zadar, Croatia.

**September 27, 2013**, 5<sup>th</sup> BBBB meeting, Invited speaker, Athens, Greece.

**October 4, 2013**, 16<sup>th</sup> Panhellenic meeting of the Hellenic Society of lipidology, Invited speaker, Athens, Greece.

**November 30, 2013**, Annual meeting of the Hellenic Atherosclerosis Society, Invited speaker, Athens, Greece.

**May 24, 2013**, 35<sup>th</sup> Annual Scientific Conference of the Hellenic Society of Biological Sciences (EEBE), Invited speaker, Nafplion, Greece.

**May 16, 2013**. Department of Chemistry, University of Patras, Invited speaker, Patras, Greece.

**May 5-7, 2013**, Annual Scientific Meeting, Biomimetics in Metabolic Syndrome, COST action CM1201, Invited speaker, Bologna, Italy.

**April 26, 2013**, The international liver congress, European Association for the study of liver (EASL), Invited speaker, Amsterdam, The Netherlands.

**May 26-June 4, 2013**. 2nd Summer School in Biomedical Sciences, World Hellenic Biomedical Association, Invited speaker, Monemvasia, Greece

**October 18, 2012**, 17<sup>th</sup> Annual meeting of the Israeli Society for the treatment and prevention of cardiovascular disease, Invited speaker, Eilat, Israel

**December 2, 2011**. Annual meeting of the Hellenic Atherosclerosis Society. Invited Speaker, Athens, Greece

**October 13-14, 2011**. 14th annual meeting of the Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease. Invited Speaker, Athens, Greece.

**August 29-September 1, 2011**. COST action BM0602 Kuopio meeting, Invited Speaker, Kuopio, Finland

**June 27-29, 2011**. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics. Invited Speaker, Budapest, Hungary

**June 17, 2011**. EMBO fellows meeting 2011. Invited speaker, Heidelberg, Germany.

**December 3, 2010**. Aristotelian University of Thessaloniki. Invited Speaker, Thessaloniki, Greece

**October 7-8, 2010**. COST action BM0602 Jerusalem meeting, Invited Speaker, Jerusalem, Israel

**August 31, 2010**. European Society of Cardiology, ESC faculty. Invited Speaker, Stockholm, Sweden. (Faculty of the ESC for the year 2010).

**September 1, 2010**. Leiden University Medical Center, Dept of Endocrinology. Invited Speaker, Leiden, The Netherlands

**June 3-6, 2010**. COST action BM0602 Toulouse meeting, Invited Speaker, Toulouse, France

**December 3-6, 2009**. COST action BM0602 Duesseldorf meeting, Invited Speaker, Duesseldorf, Germany

**August 19, 2009**. XXIV FeSBE meeting. Invited Speaker, Sao Paulo, Brazil.

**June 18, 2009**. EMBO fellows meeting 2009. Invited speaker, Heidelberg, Germany.

**March 26, 2009**. Pharmacogenomics and personalized medicine. Invited speaker, IIBEAA, Athens, Greece.



## **PRIOR TO MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

**April 17, 2007.** 3rd Romanian Meeting on Translational Medicine. Invited Speaker, Bucharest, Romania.

**September 9, 2004.** Olympic HDL meeting. Invited Speaker, Crete, Greece

**October 14 2004.** ICBP-NS. Invited Speaker, Bucharest, Romania.

**November 12 2003.** TNO-PG Prevention and Health, Department of Pharmacology, Lipidology Unit. Invited Speaker, Leiden, The Netherlands

**April 7, 2002.** Irvine H. Page Atherosclerosis Research Award Ceremony. ATVB council of the American Heart Association. Honored speaker, Salt Lake City, Utah, USA.

## **10. PATENTS**

### **AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

1. LCAT as a novel pharmaceutical target for the treatment of NAFLD (application number PCT/GR2011/000026).
2. “Therapy For Apolipoprotein-Induced Hypertriglyceridemia” (application number PCT/GR2008/000055)

### **PRIOR TO MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

1. “Compounds and methods in lowering lipid cholesterol without triggering hypertriglyceridemia” (U.S. Serial No. 09827,854 issued April 6, 2006)
2. “Methods and compositions for treating hypercholesterolemia” (U. S. Patent No. 7,309,606 issued December 18, 2007)

## 11. TEACHING EXPERIENCE

### AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

#### Undergraduate courses

Medical Pharmacology I, 2008-Present.

Medical Pharmacology laboratory I, 2008-Present.

Medical Pharmacology II, 2008- Present.

Medical Pharmacology laboratory II, 2008- Present.

Pharmacogenomics 2008-Σήμερα.

#### Graduate courses

Graduate Pharmacology. 2008- Present.

Molecular Pharmacology. 2009-2010.

Molecular Medicine. 2012-Present.

Methodology in Pharmacological Research. 2008- Present.

Invited speaker seminars. 2008- Present.

Design, development and evaluation of lead pharmacological compounds.  
2012- Present.

Research Topics. 2008-2009

### PRIOR TO MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

**Molecular basis of dyslipidemias.** 2006-2008. Part of the Molecular Medicine course offered as elective course to Boston University Medical Students. Coordinator: Prof. Vassilis I. Zannis.

**Lipoprotein Metabolism.** 2006-2008. Part of the medical Biochemistry course, Boston University Medical School. Coordinator: Prof. Abdul Traish.

## 12. PARTICIPATION IN THESIS COMMITTEES

### MEMBER OF ADVISORY COMMITTEES FOR MASTER THESES

1. 30/10/2013. **Όνομα φοιτητή:** Μαριλένα Καραβυράκη. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». (Επιβλέπων).
2. 30/10/2013. **Όνομα φοιτητή:** Ευγενία Παπακώστα. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». (Επιβλέπων).
3. 13/5/2013. **Όνομα φοιτητή:** Αλέξανδρος Κοκκόσης. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα τμήματος Βιολογίας Παν. Πατρών (Μέλος τριμελούς επιτροπής).
4. 15/5/2012. **Όνομα φοιτητή:** Ευαγγλία Ζβίντζου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Ποιοτικός και λειτουργικός χαρακτηρισμός της HDL παχύσαρκων ασθενών πριν και μετά γαστροοισοφαγική εκτομή κατά Roux et Y» (Επιβλέπων).
5. 13/5/2013. **Όνομα φοιτητή:** Αναστάσιος Νάτσος. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Ρόλος της HDL στον προκαλούμενο από υπογοναδισμό διαβήτη τύπου II με στόχο την ανάπτυξη καινοτόμων αντιδιαβητικών θεραπειών» (Επιβλέπων).
6. 13/5/2013. **Όνομα φοιτητή:** Εύα Ξεπαπαδάκη. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Ρόλος των πρωτεϊνικών συστατικών του μεταβολικού μονοπατιού της HDL στο διαβήτη με στόχο την ανάπτυξη καινοτόμων αντιδιαβητικών θεραπειών» (Επιβλέπων).
7. 20/12/2010. **Όνομα φοιτητή:** Χριστίνα Συμεού. **Πρόγραμμα:** Διατμηματικό μεταπτυχιακό πρόγραμμα «Εφαρμογές στην Ιατρική Χημεία». **Θέμα:** «Μεταβολή των επιπέδων του μεταγραφικού παράγοντα CREB μετά από διέγερση α2-αδρενεργικών υποδοχέων σε κύτταρα PC12»
8. 3/5/2011. **Όνομα φοιτητή:** Χρυσούλα Κοντοπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Κλωνοποίηση και χαρακτηρισμός της πρωτεϊνικής υπομονάδας Por5 του ριβονουκλεοπρωτεϊνικού συμπλόκου της ριβονουκλεάσης Ρ»
9. 3/5/2011. **Όνομα φοιτητή:** Κωνσταντίνος Θεοδωρόπουλος. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Μελέτη της αντιδραστικότητας των αιμοπεταλίων σε ασθενείς με STEMI που υποβάλλονται σε πρωτογενή αγγειοπλαστική μετά από δόση φόρτισης με κλοπιδογρέλη»
10. 3/5/2011. **Όνομα φοιτητή:** Ανθούλα Κάβο. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Ποιοτικός και λειτουργικός χαρακτηρισμός της HDL νεαρών ασυμπτωματικών εμφραγματιών». (Επιβλέπων)
11. 3/5/2011. **Όνομα φοιτητή:** Διογένης Μπατσούλης. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Μεταβολικές επιπτώσεις της αποστέρησης τεστοστερόνης σε μοντέλα αρρένων μυών» (Επιβλέπων)

12. 3/5/2011. **Όνομα φοιτητή:** Περιστέρα-Ιωάννα Πετροπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Μελέτη των περιοχών της απολιποπρωτεΐνης Ε που διαμεσολαβούν την de novo βιοσύνθεση HDL σε πειραματικά μοντέλα ποντικών» (Επιβλέπων)
13. 15/5/2012. **Όνομα φοιτητή:** Αγγελική Λαμπροπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Φαρμακοδυναμικός και φαρμακοκινητικός χαρακτηρισμός μιας μεταλλαγμένης μορφής της απολιποπρωτεΐνης Ε με βελτιωμένες βιολογικές ιδιότητες» (Επιβλέπων).
14. 1/9/2006. **Όνομα φοιτητή:** Rami Abdu, **Πρόγραμμα:** Master program in Graduate Medical Sciences, Boston University School of Medicine. **Θέμα:** «Structure function analysis of human apolipoprotein CIII using adenovirus mediated gene transfer» (Επιβλέπων).
15. 1/9/2008. **Όνομα φοιτητή:** Robert Feely, **Πρόγραμμα:** Master program in Graduate Medical Sciences, Boston University School of Medicine. **Θέμα:** « The Dark Side of Testosterone Deficiency: Metabolic Syndrome & Erectile Dysfunction» (Επιβλέπων).

#### MEMBER OF ADVISORY COMMITTEES FOR PH.D THESES

1. 11/6/2013. **Όνομα φοιτητή:** Ειρήνη Κωστοπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις Βασικές Ιατρικές Επιστήμες». **Θέμα:** «Αρνητική ρύθμιση της μεταβίβασης του σήματος της αυξητικής ορμόνης σε παιδιά με ανεπάρκεια αύξησης» (Μέλος επταμελούς εξεταστικής επιτροπής).
2. 11/6/2013. **Όνομα φοιτητή:** Οδυσσέας Δημητρακόπουλος. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Κλινικές και κλινικοεργαστηριακές ειδικότητες». **Θέμα:** «Μελέτη ανοσολογικών μηχανισμών που ενέχονται στη χρονιότητα της λοίμωξης με brucella» (Μέλος επταμελούς εξεταστικής επιτροπής).
3. 11/6/2013. **Όνομα φοιτητή:** Γεώργιος Κασσίμης. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις Βασικές Ιατρικές Επιστήμες». **Θέμα:** «Μελέτη πολυμορφισμών του DNA που συσχετίζονται με την αντίσταση στο αντιαιμοπεταλιακό φάρμακο κλοπιδογρέλη» (Μέλος επταμελούς εξεταστικής επιτροπής).
4. 11/6/2013. **Όνομα φοιτητή:** Θεώνη Καβέλη. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Κλινικές και κλινικοεργαστηριακές ειδικότητες». **Θέμα:** «Μελέτη του ρόλου της συνεργασίας σηματοδοτικών οδών ενεργοποιούμενων από ενδοκυττάρια και εξωκυττάρια υποδοχείς φυσικής ανοσίας στον έλεγχο της λοίμωξης από brucella σε ανθρώπινα κύτταρα» (Μέλος τριμελούς συμβουλευτικής επιτροπής).
5. 04/2/2013. **Όνομα φοιτητή:** Περιστέρα-Ιωάννα Πετροπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις Βασικές Ιατρικές Επιστήμες». **Θέμα:** «Μελέτη των πρωτεϊνών του μεταβολικού συστήματος της HDL στη θεραπεία της φλεγμονής και της σήψης που προκαλείται από λιποσακχαρίτη» (Επιβλέπων).
6. 01/3/2013. **Όνομα φοιτητή:** Κατερίνα Χατζίρη. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις Βασικές Ιατρικές

- Επιστήμες». **Θέμα:** «Το σύστημα των χυλομικρών του πλάσματος ως φαρμακολογικός στόχος για την θεραπεία της νοσογόνου παχυσαρκίας και άλλων συνοδών νοσημάτων του μεταβολικού συνδρόμου» (Επιβλέπων).
7. **3/5/2011. Όνομα φοιτητή:** Δημήτριος Ζαμπέτας. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Κλινικές-κλινικοεργαστηριακές Ιατρικές Ειδικότητες». **Θέμα:** «Οι γλυκάνες στη σχέση παθογόνου-ξενιστή στη σήψη»
  8. **3/5/2011. Όνομα φοιτητή:** Αρτεμisia Μοσχοπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Κλινικές-κλινικοεργαστηριακές Ιατρικές Ειδικότητες». **Θέμα:** «Παθογενετικοί μηχανισμοί, προκαλούμενης από άτυπα αντιψυχωσικά, δυσλιπιδαιμίας»
  9. **23/5/2011. Όνομα φοιτητή:** Ιωάννα Βαλλιάνου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα Τμήματος Βιολογίας ΑΠΘ. **Θέμα:** «Μοριακοί μηχανισμοί της αντι-υπερ-λιπιδαιμικής δράσης του μαστιχαίλαιου σε πειραματικά μοντέλα ποντικών»
  10. **20/12/2011. Όνομα φοιτητή:** Ελένη Καλυβιώτη. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «θα οριστεί»
  11. **20/12/2011. Όνομα φοιτητή:** Περιστέρα-Ιωάννα Πετροπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Μελέτη του ρόλου των πρωτεϊνών της HDL στη φλεγμονή και στην παχυσαρκία» (Επιβλέπων)
  12. **7/3/2012. Όνομα φοιτητή:** Κεφαλά Σωτηρία. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Φαρμακολογικές εφαρμογές της παρστατίνης ως αναστολέα της αγγειογένεσης»
  13. **26/6/2012. Όνομα φοιτητή:** Ελένη Οικονόμου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες». **Θέμα:** «Μελέτη της έκφρασης της ακουοπορίνης 7 στο λιπώδη ιστό στα παιδιά και η διερεύνηση της συμμετοχής της σε μηχανισμούς ανάπτυξης νοσογόνου παχυσαρκίας»
  14. **26/6/2012. Όνομα φοιτητή:** Ιωάννα Παρτσαλάκη. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Κλινικές-κλινικοεργαστηριακές Ιατρικές Ειδικότητες». **Θέμα:** «Επίδραση διαφόρων διαιτών απώλειας βάρους στο οξειδωτικό στρες και στους αντιοξειδωτικούς μηχανισμούς παχύσαρκων παιδιών»
  15. **27/6/2012. Όνομα φοιτητή:** Ελένη Καραβία. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις Βασικές Ιατρικές Επιστήμες». **Θέμα:** «Τα συστατικά στοιχεία του συστήματος λιπιδίων και λιποπρωτεϊνών ως κεντρικοί ρυθμιστές στην εμφάνιση παχυσαρκίας και μη αλκοολικής λιπώδους νόσου του ήπατος σε πειραματικά μοντέλα ποντικών» (Επιβλέπων)

## MEMBER OF EXAM COMMITTEES FOR PH.D DEGREES

1. 15/5/2007. **Όνομα φοιτητή:** Gerry Gerritsen. **Πρόγραμμα:** Graduate studies in Basic Medical Sciences, Leiden University School of Medicine.  
**Θέμα:** «Mechanisms of apolipoprotein induced dyslipidemia in mice»
2. 6/5/2010. **Όνομα φοιτητή:** Βασιλική Σταματοπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες».  
**Θέμα:** «Μελέτες επί της δομής και λειτουργίας πρωτεϊνικών υπομονάδων του ριβονουκλεοπρωτεϊνικού συμπλόκου της ριβονουκλεάσης Ρ από το dictyostelium discoideum»
3. 3/5/2011. **Όνομα φοιτητή:** Βασιλική Σταματοπούλου. **Πρόγραμμα:** Μεταπτυχιακό πρόγραμμα «Εφαρμογές στις βασικές ιατρικές επιστήμες».  
**Θέμα:** «Η συσχέτιση των τελικών προϊόντων προχωρημένης γλυκοζυλίωσης του υποδοχέα τους και του διαλυτού τμήματος του σε παιδιά και εφήβους με Σακχαρώση Διαβήτη τύπου Ι»

### **13. REVIEWER FOR INTERNATIONAL FUNDING AGENCIES**

#### **AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

**Reviewer for the Netherlands Organization for Scientific Research (NWO),** October 2013, Netherlands-Brazil bilateral research program.

**Abstract evaluator for the 82nd European Atherosclerosis Society Congress** (EAS 2014), Madrid, Spain.

**Research Foundation Flanders FWO (Fonds Wetenschappelijk Onderzoek – Vlaanderen).** Μάιος 2011-Σήμερα. Μέλος των επιτροπών αξιολόγησης προγραμμάτων με τριετή θητεία.

**Israel Science Foundation (ISF).** 14 Μάρτιος 2011 ,14 Απριλίου 2012, 5 Μαΐου 2014. Μέλος της επιτροπής αξιολόγησης προγραμμάτων.

**Romanian National University Research Council (NURC).** 10 Οκτωβρίου 2008. Μέλος της επιτροπής αξιολόγησης στην κατηγορία “Complex projects”

#### **PRIOR TO MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

**American Heart Association,** NorthEast division, evaluator in Scientist Development Grants



## **14. PARTICIPATION IN GREEK AND INTERNATIONAL RESEARCH NETWORKS**

### **AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

**University of Patras research network MetSNet.** 2009-Present. Coordinator. MetSNet was recently evaluated by the independent evaluation committee and was selected as one of the five most active University networks based on activity and funding. Metsnet website can be access at [www.metsnet.gr](http://www.metsnet.gr)

**University of Patras research network OSTEONET.** 2011-Present. Member (coordinator Dr. D. Papachristou)

**BMBS COST Action BM0602, Adipose Tissue: A Key Target for Prevention of the Metabolic Syndrome.** 2008-2012. Εθνικός αντιπρόσωπος και μέλος της συντονιστικής επιτροπής. Μέλος της ομάδας εργασίας: Gluco-lipotoxicity, islet inflammation, beta cell dysfunction and type 2 diabetes.

**CMST COST Action CM1201 Biomimetic Radical Chemistry in Human Health.** 2012-2016. Αναπληρωματικό μέλος της συντονιστικής επιτροπής. Μέλος της ομάδας εργασίας: membrane lipids in stress and ageing;

**European Lipoprotein Club. Tutzing, Germany,** 2000-Σήμερα. Μέλος

### **PRIOR TO MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

**Hellenic Bioscientific Association (HBA-USA),** 2004-2008. Γραμματέας του διοικητικού συμβουλίου για την περίοδο 2004-2005 και εν συνεχεία Μέλος.

**New England lipid group.** 2000-2008. Μέλος.

**Dutch Lipoprotein Club.** 2000-2004. Μέλος.

## 15. PARTICIPATION IN THE EDITORIAL BOARD OF PEER-REVIEWED INTERNATIONAL JOURNALS

**AJP Endocr. Metabol.** 2011-Present. Member of the Editorial Board

**Guest Editor, FEBS Journal.** 2009. Guest Editor for the minireviews entitled “Mechanisms of obesity and related pathologies”. Συμμετέχοντες στη σειρά ήταν οι Drs. A. Traish, K. Karalis, S. Farmer, P. Scherer, and myself.

**Clinical Lipidology.** April 2012. Invited Editorial Contributor: “HDL quality in atherosclerosis: can ratios between apolipoproteins of HDL be used effectively to indicate risk of premature myocardial infarction?”

**Research Journal of Endocrinology and Metabolism,** January 2013-Present. Member of the Editorial Board με εξειδίκευση στη Φαρμακολογία των δυσλιπιδαιμιών, της αθηρωμάτωσης, και του Μεταβολικού Συνδρόμου

## 16. REVIEWER IN INTERNATIONAL PEER-REVIEWED JOURNALS

AJP Endocrinology and Metabolism  
American Journal of Physiology Gastro and Liver  
Archives of Physiology and Biochemistry  
Atherosclerosis, thrombosis, and vascular biology  
Biochemical Pharmacology  
Biochemistry  
British Journal of Pharmacology  
Circulation  
Clinical Lipidology  
Diabetes metabolism research and reviews  
Endocrinology  
European Journal of Clinical Pharmacology  
European Journal of Internal Medicine  
FASEB J  
FEBS J  
Hormone and Metabolic Research  
International journal of medical sciences  
Immunobiology  
Journal of Biological Chemistry  
Journal of cellular and molecular medicine  
Journal of lipid research  
Journal of nutritional biochemistry  
Molecular genetics and metabolism  
Molecular nutrition and food research  
Molecular pharmacology  
Pharmacogenomics  
Plos One  
Vascular pharmacology

## 17. ADMINISTRATIVE POSITIONS

1. **Member of the managing board of the Hellenic Bioscientific Association HBA-USA, 2004-2005.**
2. **Chairman and financial officer of the sector of Basic Medical Sciences II of the University of Patras Department of Medicine. September 2011-August 2013.**
3. **Chairman of the e-class and medical libraru committee of the University of Patras Department of Medicine. September 2012-Present**
4. **Member of the qualifying committee of the graduate program “Appications in Basic Medical Sciences” of the University of Patras Department of Medicine. September 2010- Present**
5. **Member of the admissions committee of the graduate program “Appications in Basic Medical Sciences” of the University of Patras Department of Medicine. September 2010- Present**
6. **Substitute member of the managing board for research administration. September 2010- Present**
7. **Member of the undergraduate medical curriculum improvement committee of the University of Patras Department of Medicine.. Academic year 2010-2011**
8. **Member of the Laboratory animal center managing committee. September 2009- Present**
9. **Coordinator of invited speaker seminar series at the Whitaker Cardiovascular Institute, Boston University School of Medicine. September 2004-April 2008.**
10. **Member of the quality assurance subcommittee for the evaluation of faculty, of the University of Patras Department of Medicine September 2013-Present**
11. **Member of the admissions committee for the Graduate program in Medical Sciences of the University of Patras Medical School. September 2013.**
12. **Member of the quality assurance committee (OMEA) of the University of Patras School of Medicine that organized the recent suvccessful external evaluation of the medical school from 18-20 November 2013.**

## **18. COMMUNITY SERVICE**

**2008-PRESENT**, Student advisor for HELMSIC members, Patras branch.

**1998-PRESENT**, Boston University GMS Alumni Mentor  
(<http://www.bumc.bu.edu/gms/gateway/students/phd/fibs-ii/gms-alumni-mentors/>)

## 19. PUBLICATIONS

### AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

1. Caterina Constantinou, Diogenis Mpatsoulis, Anastasios Natsos, Peristera-Ioanna Petropoulou, Evangelia Zvintzou, Abdulmaged M. Traish, Peter J. Voshol, Iordanes Karagiannides, and **Kyriakos E. Kypreos** (2014) The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations. *J Lipid Res.* (In press)
2. E Zvintzou, G Skroubis, A Chroni, P Petropoulou, C Gkolfinopoulou, G Sakellaropoulos, D Gantz, I Mihou, F Kalfarentzos, and **Kyriakos E. Kypreos** (submitted) Effects of weight loss on HDL particle structure and functionality following malabsorptive bariatric surgery, *Journal of Clinical Lipidology* (in press)
3. Karavia EA, Zvintzou E, Petropoulou PI, Xepapadaki E, Constantinou +, **Kyriakos E. Kypreos** (2014) HDL quality and functionality: what can proteins and genes predict? *Expert Rev Cardiovasc Ther.* 2014 Apr; 12(4):521-32. doi: 10.1586/14779072.2014.896741.
4. **Kyriakos E. Kypreos.**, Sonja Zafirovic, Peristera-Ioanna Petropoulou, Predrag Bjelogrić, Ivana Resanovic, Abdul Traish , and Esma R. Isenovic (2014) Regulation of eNOS and HDL quality by estradiol in cardiovascular pathology," *Journal of Cardiovascular Pharmacology and Therapeutics*, 19(3):256-68.
5. **Kypreos KE**, Gkizas S, Rallidis LS, Karagiannides I. (2013) HDL particle functionality as a primary pharmacological target for HDL-based therapies. *Biochem Pharmacol.* 2013 Mar 13. pii: S0006-2952(13)00161-5. doi: 10.1016/j.bcp.2013.03.004. (IF=4.705, citations=13)
6. Georgiadou D, Chroni A, Drosatos K, **Kyriakos E. Kypreos**, Zannis VI, Stratikos E. (2012) Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles. *Atherosclerosis.* Nov 23. pii: S0021-9150(12)00808-8. doi: 10.1016/j.atherosclerosis.2012.11.013. (IF=4.522, citations=0)
7. Lampropoulou A and **Kyriakos E. Kypreos** (2012) Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties. *Biochem. Pharmacol.* 84(11):1451-8. doi: 10.1016/j.bcp.2012.09.006. (IF=4.254, citations=1)
8. Irene-Eva Triantaphyllidou, Eleni Karavia, Eleni Kalyvioti, Ioannis Lilis, **Kyriakos E. Kypreos**, and Dionysios J. Papachristou (2012) Lecithin:cholesterol acyltransferase deficiency predisposes to the development of osteoarthritis in mice following long-term exposure to Western-type diet. *Osteoarthritis and Cartilage.*, doi:pii: S1063-4584(12)01016-3. 10.1016/j.joca.2012.11.003. (IF=3.888, citations=0)

9. Eleni A. Karavia, Dionysios J. Papachristou, Kassiani Liopeta, Irene-Eva Triantafyllidou, Odyssefs Dimitrakopoulos, and **Kyriakos E. Kypreos** (2012) Apolipoprotein A-I modulates Processes Associated with Diet-Induced Nonalcoholic Fatty Liver Disease in Mice *Mol. Med.*, 18:901-12. doi: 10.2119/molmed.2012.00113. (IF=5.020, citations=1)
10. **Kyriakos E. Kypreos** (2012) HDL Quality in Atherosclerosis: can ratios between apolipoproteins of HDL be used effectively to indicate risk of premature myocardial infarction? *Clin. Lipidol.* 7:127-29. (*Invited Editorial*). (IF= 0.954, citations=0)
11. Eleni Karavia, Dionysios J. Papachristou, Ioanna Kotsikogianni, Irene-Eva Triantafyllidou, and **Kyriakos E. Kypreos** (2012) Lecithin:cholesterol acyltransferase modulates the severity of diet-induced nonalcoholic fatty liver disease in mice. *J. Nutr. Biochem.* DOI: 10.1016/j.jnutbio.2012.02.007. (IF=4.288, citations=1)
12. Anthula E. Kavou, Loukianos Rallidis, George C. Sakellaropoulos, Stefan Lehr, Sonja Hartwig, Juergen Eckel, Polixeni Mpozatzi, Panagiota Tsikrika, and **Kyriakos E. Kypreos** (2012) Qualitative characteristics of HDL particles in young asymptomatic patients of an acute myocardial infarction. *Atherosclerosis*, 220:257-64. (IF=4.522, citations=1)
13. Eleni Karavia, Dionysios J. Papachristou, Ioanna Kotsikogianni and **Kyriakos E. Kypreos** (2011) Deficiency in Apolipoprotein E has a Protective effect on Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. *FEBS J*, 278:3119-29. (IF= 3.042, citations=4)
14. Peristera A. Petropoulou, Donald L. Gantz, Yanan Wang, Patrick C.N. Rensen, and **Kyriakos E. Kypreos** (2011). The aminoterminal 1-185 domain of human apolipoprotein E suffices for the *de novo* biogenesis of apoE-containing HDL. *Atherosclerosis*, 219:116-23. (IF=4.522, citations=0)
15. Abdul Traish and **Kyriakos E. Kypreos** (2010) Testosterone and Cardiovascular Disease: An Old Idea with Modern Clinical Implications, *Atherosclerosis*, 214:244-8. (IF= 4.522, citations=18)
16. Eirini M. Tsompanidi, Maria S. Brinkmeyer, Elisavet H. Fotiadou, Smaragda M. Giakoumi, and **Kyriakos E. Kypreos** (2010) HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis. *Atherosclerosis*, 208: 3-9. (IF=4.522, citations= 41)
17. Abdulmaged M. Traish, Rami Abdou, and **Kyriakos E. Kypreos** (2009) Androgen deficiency and atherosclerosis: The lipid link. *Vascul Pharmacol.* 51: 303-13. (IF=2.044, citations=33)
18. **Kyriakos E. Kypreos**, Iordanes Karagiannides, Elisavet Fotiadou, Eleni A. Karavia, Maria Brinkmeier, Smaragda M. Giakoumi, Eirini Tsompanidi (2009) Mechanisms of obesity and related pathologies: Apolipoprotein E in the development of obesity. *FEBS J* 276: 5720-8. (IF= 3.042, citations=14)
19. **Kyriakos E. Kypreos** (2009) Mechanisms of obesity and related pathologies commentary. Commentary *FEBS J* 276: 571 (IF= 3.042, citations=4)
20. Sarmiento J, **Kyriakos E. Kypreos**, Prado GN, Suetomi K, Stanzel C, Maxwell C, Shumate D, Tandang-Silvas MR, Rajarathnam K, Navarro J. (2009) Adenovirus mediated expression "in vivo" of the chemokine receptor CXCR1. *J Struct Funct Genomics.* 10:17-23. (IF=2.642, citations=3)
21. Gorshkova IN, Kypreos KE, Gantz DL, Zannis VI, Atkinson D. (2008) Biophysical properties of apolipoprotein E4 variants: implications in

- molecular mechanisms of correction of hypertriglyceridemia. *Biochemistry* **47**:12644-54. (IF= 3.226, citations=9)
22. **Kyriakos E. Kypreos** (2008) ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of Apolipoprotein CIII-induced hypertriglyceridemia. *Biochemistry*, **47**: 10491-502. (IF=3.226, citations=19)
23. Iordanes Karagiannides, Rami Abdou, Aikaterini Tzortzopoulou, Peter Voshol and **Kyriakos E. Kypreos** (2008) Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. *FEBS J*, **275**: 4796-809. (IF= 3.042, citations=29)
24. Vassilis I. Zannis, George Koukos, Konstantinos Drosatos, Alexander Vezeridis, Eleni E. Zanni, **Kyriakos E. Kypreos**, Angelika Chroni. (2008) Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. *Ann Med.* **40** Suppl 1:14-28. (IF= 5.435, citations=13)
25. Hu L, Van der Hoogt CC, Espirito Santo SM, Out R, **Kyriakos E. Kypreos**, Van Vlijmen BJ, Van Berkel TJ, Romijn JA, Havekes LM, Willems van Dijk K, Rensen PC (2008). The hepatic uptake of VLDL in absence of the three major apoE-recognizing receptors is regulated by LPL activity and involves heparan sulfate proteoglycans and scavenger receptor BI. *J Lipid Res.* **49**:1553-61 (IF= 4.917, citations=21)
26. Gerritsen G, van der Hoogt CC, Schaap FG, Voshol PJ, **Kyriakos E. Kypreos**, Maeda N, Groen AK, Havekes LM, Rensen PC, van Dijk KW (2008). ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency. *J Lipid Res.* **49**:1048-55. (IF=4.917, citations=4)

## PRIOR MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

27. Constantinos Drosatos, Despina Sanoudou , **Kyriakos E. Kypreos**, Dimitris Kardassis, Vassilis I. Zannis (2007) “A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice” *J Biol Chem.* **282**:19556-64. (IF= 5.328, citations=12)
28. Constantinos Drosatos, **Kyriakos E. Kypreos**, Vassilis I. Zannis (2007) “Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein” *Biochemistry*, **46**:9645-53. (IF=3.226, citations=3)
29. **Kyriakos E. Kypreos** and Vassilis I. Zannis. (2007) “Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT” *Biochem J*, **403**: 359-67. (IF= 5.155, citations=32)
30. Iordanes Karagiannides, Thomas Thomou, Tchkonina T, Pirtskhalava T, **Kyriakos E. Kypreos**, Cartwright A, Dalagiorgou G, Lash TL, Farmer SR, Timchenko NA, Kirkland JL. (2006) Increased CUG triplet repeat-binding



- protein-1 predisposes to impaired adipogenesis with aging. *J. Biol. Chem.*, **32**: 23025-33. (IF= 5.328, citations=28)
31. **Kyriakos E. Kypreos** and Vassilis I. Zannis. (2006) "The LDL receptor can account for the clearance for the apoE containing lipoprotein remnants in mice; LDL receptor deficiency or apoE mutations increase sensitivity to hypertriglyceridemia" *J. Lipid Res.*, **47**: 521-9 (IF= 4.917, citations=26)
  32. Gery Gerritsen, Patrick Rensen, **Kyriakos E. Kypreos**, Vassilis I. Zannis, Louis M. Havekes, Ko Willems van Dijk (2005) ApoCIII deficiency prevents hyperlipidemia induced by apoE overexpression. *J. Lipid Res.*, **46**: 1466-73 (IF= 4.917, citations=14)
  33. Angeliki Chroni, Anthony Nieland, **Kyriakos E. Kypreos**, Monty Krieger, Vassilis I. Zannis, "SR-BI-mediates cholesterol efflux via interactions with lipid-bound apoE. Structural mutations in SR-BI diminish receptor binding and cholesterol efflux". *Biochemistry*, **44**:13132-43. (IF= 3.226, citations=38)
  34. **Kyriakos E. Kypreos**, Ko Willems van Dijk, Louis M. Havekes, and Vassilis I. Zannis. (2005) "Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues L261, W264, F265, L268, V269 of apoE can account for the apoE-induced hypertriglyceridemia". *J. Biol. Chem.* **280**: 6276 – 6284 (IF=5.328, citations=37)
  35. Angeliki Chroni\*, Horng-Yuan Kan\*, **Kyriakos E. Kypreos\***, Irina Gorshkova Adelina Shkodrani, and Vassilis I. Zannis (2004) "Substitutions of Glu110, Glu111 in the middle helix 4 of human APOA-I by Ala affect the structure and the in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I deficient mice" *Biochemistry* **43**: 10442-57. **\*Equal contribution to this work, Co-first authorship** (IF= 3.226, citations=36)
  36. Vassilis I. Zannis, Angelika Chroni\*, **Kyriakos E. Kypreos\***, Horng-Yuan Kan†, Thais Borges Cesar, Eleni Zanni, and Dimitris Kardassis (2004) "Probing the pathways of Chylomicron and HDL metabolism using adenovirus mediated gene transfer" *Curr. Opin. Lipid.* **15**: 151-166 **\*Equal contribution** (IF= 6.133, citations=52)
  37. Xiaoping Li, **Kyriakos E. Kypreos**, Eleni E. Zanni, and Vassilis I. Zannis. (2003) "Domains of apoE Required for Binding To apoE Receptor 2 and To Phospholipids: Implications For The Functions Of apoE in the Brain", *Biochemistry* **42**: 10406-10417 (IF=3.226, citations= 46)
  38. **\*\*Kyriakos E. Kypreos**, Xiaoping Li, Ko Willems van Dijk , Louis M. Havekes, Vassilis I. Zannis. (2003) "Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype". *Biochemistry* **42**: 9841-9853. **\*\*For this work I received the annual Irvine Page Award for the year 2002 by the ATVB council of the American Heart Association.** (IF=3.226, citations=44)
  39. Gery Gerritsen, **Kyriakos E. Kypreos**, Andre van der Zee, Vassilis I. Zannis, Louis M. Havekes, Ko Willems van Dijk. (2003) "Hyperlipidemia in ApoE2 transgenic mice is aggravated by overexpression of full length apoE3 whereas it is reduced by a truncated apoE variant. *J. Lipid Res.* **44**: 408-414. (IF= 4.917, citations=8)
  40. **Kyriakos E. Kypreos** (2002) "Apolipoprotein E and gene therapy", *BIO.* **2**: 62-65. (Greek)

41. **Kyriakos E. Kypreos**, Morani P., van Dijk K.-W., Havekes L.M., and Zannis V.I. (2001) The aminoterminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants *in vivo*. The carboxyterminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice *Biochemistry* **40**: 6027-6035. (IF=3.226, citations=32)
42. **Kyriakos E. Kypreos**, van Dijk K.-W., van der Zee A., Havekes L.M., and Zannis V.I. (2001) Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis *in vivo*: the carboxyterminal region 203-299 promotes hepatic VLDL-triglyceride secretion. *J. Biol. Chem.* **276**: 19778-86. (IF=5.328 , citations=55)
43. **Kyriakos E. Kypreos**, Tuesink B., van Dijk K.-W., Havekes L.M., and Zannis V.I. (2001) Analysis of the Structure-Function Relationship of the Human Apolipoprotein E, using Adenovirus Mediated Gene Transfer. *FASEB J.* **15**: 1598-1600. (IF=6.401, citations=43)
44. **Kyriakos E. Kypreos**, Birk, D.E., Trinkaus-Randall V., Hartmann, D.J. and Sonenshein G.E. (2001) Type V Collagen Regulates the Assembly of Collagen Fibrils in Cultures of Bovine Vascular Smooth Muscle Cells. *J. Cell. Biochem.* **80**, 146-155. (IF= 2.935, citations=26)
45. **Kyriakos E. Kypreos**, Marhamati D.J. and Sonenshein G.E. (1999) B-Myb represses trans-activation of the Col5A2 collagen promoter indirectly via inhibition of binding of factors interacting with positive elements within the first exon. *Matrix Biol.* **18**, 275-85. (IF= 3.558, citations=10)
46. **Kyriakos E. Kypreos** and Sonenshein, G.E. (1998) Basic fibroblast growth factor decreases type V/XI collagen expression in cultured bovine aortic smooth muscle cells. *J. Cell. Biochem.* **68**, 247-258. (IF= 2.935, citations=15)
47. Lee, J.E., **Kyriakos E. Kypreos**, and Sonenshein, G.E. (1998) Synchronization of cultured vascular smooth muscle cells following reversal of quiescence induced by treatment with the antioxidant N-acetylcysteine. *Exp. Cell Res.* **239**, 447-453. (IF= 3.010, citations=14)
48. **Kyriakos E. Kypreos**, Nugent M.A. and Sonenshein, G.E. (1998) Basic fibroblast growth factor decrease in type I collagen gene transcription is mediated by B-myb. *Cell Growth and Differentiation.* **9**, 723-730. (IF= 3.337, citations=19)
49. Marhamati, D.J., Bellas, R.E., Arsur, M., **Kyriakos E. Kypreos** and Gail E. Sonenshein. (1997) A-myb is expressed in bovine vascular smooth muscle cells during the late G<sub>1</sub>-to-S phase transition and cooperates with c-myc to mediate progression to S phase. *Mol. Cell. Biol.* **17**, 2448-2457. (IF= 6.057, citations=40)

#### **BOOK CHAPTERS:**

#### **AFTER APPOINTMENT AT THE UNIVERSITY OF PATRAS**

1. Ko Willems van Dijk, **Kyriakos E. Kypreos**, Fritz J. Fallaux, Hageman J. Adenovirus-mediated gene transfer. *Methods Mol Biol.* 2011;693:321-43. (citations=10)
2. Eleni Karavia and **Kyriakos E. Kypreos** (2010) "HDL and cardiovascular disease" in *From Vascular Cell Biology to Cardiovascular Medicine* (Georgescu A., eds) (ISBN 978-81-7895-503-2).

## PRIOR MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

3. Vassilis I. Zannis, Kyriakos E. Kypreos, Angeliki Chroni, Dimitris Kardassis and Eleni E. Zanni (2004) "Lipoproteins and atherogenesis" in *Molecular Mechanisms of Atherosclerosis* (Loscalzo, J.L., eds) (ISBN 1-84214-243-70). (citations=23)
4. van Dijk, K.W., Kyriakos E. Kypreos, d'Oliveira, C., Fallaux, F.J. (2003) Adenovirus mediated gene transfer. *Methods Mol. Biol.* **209**: 231-247. (citations=5)
5. Kyriakos E. Kypreos, Marhamati, D.J., Nugent, M.A., and Sonenshein, G.E (1999) "B-Myb Represses Collagen Gene Expression in Bovine Vascular Smooth Muscle Cells." in *The fetal and Neonatal Pulmonary Circulations (AHA Monograph Series)*, (Weir K. E., Archer S. L. and Reeves, J. T. eds) pp. 171-199.
6. Kyriakos E. Kypreos, and Sonenshein, G.E. (1998) "Collagen gene expression in vascular smooth muscle cells: Inhibition by B-Myb." in *Extracellular Matrix-Cell Interaction* (Edited by Ooyama T, Olsen B, Ninomiya Y, Grinnel F, Nishida T, and Boyd CD), Japan Scientific Society Press, Tokyo.

## PUBLICATIONS IN GREEK JOURNALS AND MAGAZINSE (without impact factor)

1. Kyriakos E. Kypreos. (2002) "Apolipoprotein E and gene therapy", **BIO**, **2**, pp 62-65.

2. Smaragda Giakoumi, Maria Brinkmeyer, Elisavet Fotiadou, Irene Tsompanidi, and Kyriakos E. Kypreos, **BIO**, **31**, pp 50-56

3. Irine Tsompanidou and Kyriakos E. Kypreos (2008) HDL and atherosclerosis, **Αθήρρωμα**, **12** (4): pp 1-2.

4. Diogenis Mpatsoulis and Kyriakos E. Kypreos (2011) Testosterone and cardiovascular disease, **Αθήρρωμα**, **15** (2): pp1-3.

Evangelia Zvintzou and Kyriakos E. Kypreos (2011) HDL apolipoprotein ratio as qualitative marker for its atheroprotective functions, **Αθήρρωμα**, **17** (1): pp1-3.

## ONLINE INVITED COMMENTARIES ΣΕ ΙΣΤΟΤΟΠΙΟΥΣ ΕΠΙΣΤΗΜΟΝΙΚΩΝ ΕΤΑΙΡΙΩΝ

1. International Atherosclerosis Society:

<http://www.athero.org/commentaries/COMM998.ASP>



## 20. PEER-REVIEWED ORAL PRESENTATIONS IN SCIENTIFIC CONFERENCES

### AFTER MY APPOINTMENT AT THE UNIVERSITY OF PATRAS

1. **\*\*July 6-11, 2013**, FEBS Congress 2013. St Petersburg, Russian Federation. Authors: Eleni A. Karavia, Dionysios J. Papachristou, and **Kyriakos E. Kypreos**. Title: Novel causative relationship between low HDL and diet-induced nonalcoholic fatty liver disease.
2. **\*\*July 6-11, 2013**, FEBS Congress 2013. St Petersburg, Russian Federation. Authors: Peristera-Ioanna Petropoulou and **Kyriakos E. Kypreos**. Title: Effects of testosterone deficiency in mice lacking the low density lipoprotein receptor.

**\*\*The researchers Eleni Karavia and Peristera-Ioanna Petropoulou were selected by the FEBS congress organizing committee for a FEBS travel scholarship based on their CVs and submitted work.**

3. **18-21 May 2013**, ECTS meeting 2013, Lisbon, Portugal, Authors: Papachristou NI, Kalyvioti ES, Triantaphyllidou I-E, Karavia E<sup>2</sup>, Plakoula E, Blair HC, **Kyriakos E. Kypreos**, Papachristou DJ. Title: Apolipoprotein-E (ApoE) deficiency prevents obesity but predisposes to the development of osteoporosis following long-term exposure to Western-type diet in mice.
4. **May 5-7, 2012**, ECTS meeting 2012, Helsinki, Finland. Authors: Kalyvioti ES, Papachristou NI, Triantaphyllidou I-E, Karavia E, Plakoula E, Blair HC, **Kyriakos E. Kypreos**, Papachristou DJ. Title: Apolipoprotein A-I deficiency is associated with decreased expression of osteoblast-specific regulators in mice.
- 5.
6. **October 19, 2012**, 17<sup>th</sup> Annual meeting of the Israeli Society for research, prevention and treatment of atherosclerosis. Authors: **Kyriakos E. Kypreos**. Title: Novel HDL based pharmacological interventions to combat the residual risk of statins and treat coronary heart disease.
7. **May 25-28, 2012**, European Atherosclerosis Society, Milan, Italy. Authors: **Kyriakos E. Kypreos**. Title: Qualitative differences in HDL isolated from young asymptomatic patients who suffered an acute myocardial infarction.
8. **May 18-20, 2012**, Annual meeting of the Hellenic Pharmacological Society, Thessaloniki, Greece. **Kyriakos E. Kypreos**. Title: Pharmacogenomics in coronary heart disease.
9. **April 17-21, 2012**. Golden Helix Symposium: Translating genes into medicines". Authors: **Kyriakos E. Kypreos**. Title: HDL in personalized treatment of coronary heart disease.
10. **December 2-3, 2011**. Annual meeting of the Hellenic Atherosclerosis Society, Athens, Greece Authors: **Kyriakos E. Kypreos**. Title: Facts and fiction about HDL. (Invited presentation)

11. **October 13-14, 2011.** 14th annual meeting of the Hellenic Society of Lipidology, Atherosclerosis and Vascular Disease, Athens, Greece. Authors: **Kyriakos E. Kypreos**. Title: Testosterone in Atherosclerosis (Invited presentation)
12. **September 5-8, 2011.** 34th ELC meeting, Tutzing, Germany. Authors: **Kyriakos E. Kypreos**. Title: Lecithin:cholesterol acyltransferase modulates the severity of diet-induced nonalcoholic fatty liver disease. (oral presentation).
13. **August 26-31, 2011.** COST action BM 0602 Conference, Kuopio, Finland. Authors: **Kyriakos E. Kypreos**. Title: Lecithin/cholesterol acyltransferase as a potential novel pharmaceutical target for the treatment of diet-induced nonalcoholic fatty liver disease.
14. **June 26-29, 2011.** 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary. Authors: **Kyriakos E. Kypreos**. Title: Lecithin:cholesterol acyltransferase modulates the severity of diet-induced nonalcoholic fatty liver disease. (Invited presentation)
15. **June 17-19, 2011.** Annual EMBO Fellows Meeting, Heidelberg, Germany. Authors: **Kyriakos E. Kypreos**. Title: My life-long devotion to the understanding and treatment of metabolic syndrome. (Invited presentation)
16. **September 6-9, 2010,** 33th ELC meeting, Tutzing, Germany. Authors: **Kyriakos E. Kypreos**. Title: HDL quality and quantity in atherosclerosis. (oral presentation).
17. **August 28-Sept. 1, 2010.** Congress of the European Society of Cardiology, Stockholm, Sweden. Authors: **Kyriakos E. Kypreos**. Title: Genetically engineered forms of apolipoprotein E for the treatment of dyslipidemia and atherosclerosis. (Invited presentation)
18. **June 3-6, 2010.** COST action BM 0602 Conference, Toulouse, France, Authors: **Kyriakos E. Kypreos**. Title: Novel animal models for the evaluation of lead compounds for the treatment of atherosclerosis.
19. **September 7-10, 2009.** 32<sup>st</sup> meeting of the European Lipid Club, Tutzing, Germany. Authors: **Kyriakos E. Kypreos**, Elisavet Fortiadou, Smaragdi Giakoumi, and Maria Brinmeyer. Title: Substitutions of L261A, W264A, F265A, L268A, and V269A in human apoE improve its ability to promote remnant clearance in mice lacking apoE and the LDL-receptor.
20. **August 19, 2009.** XXIV FeSBE meeting, Sao Paulo, Brazil. Authors: **Kyriakos E. Kypreos**. Title: Development of novel apoE-based lead biological drugs for the treatment of dyslipidemia and atherosclerosis.
21. **September 8-11, 2008.** 31<sup>st</sup> meeting of the European Lipid Club, Tutzing, Germany. Authors: Iordanes Karagiannides, Rami Abdou, Aikaterini Tzortzopoulou, Peter Voshol, and **Kyriakos E. Kypreos**. Title: Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice.

#### **PRIOR MY MY APPOINTMENT AT THE UNIVERSITY OF PATRAS**

22. **November 13-16, 2006.** 78th Scientific Sessions of the American Heart Association, Dallas, Texas, USA. Authors: **Kyriakos E. Kypreos** and Vassilis I. Zannis. Title: Novel pathway of biogenesis of apoE-containing HDL with the participation of abca1 and lcat: implications for dyslipidemias and atherogenesis, Circulation Supplement, 112: pp II-170

23. **November 7-10, 2004.** 77<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, Louisiana, USA. Authors: **Kyriakos E. Kypreos**, and Zannis V.I. Title: The LDL receptor is the only physiological receptor for the in vivo clearance of apoE-containing lipoprotein remnants in mice, *Circulation* Supplement, 110: pp III-37
24. **November 7-10, 2004.** 77<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, Louisiana, USA. Authors: **Kyriakos E. Kypreos**, and Zannis V.I. Title: Generation of a recombinant apolipoprotein E variant with improved biological functions: Residues (L261, W264, F265, L268, V269) of apoE can account for the apoE-induced hypertriglyceridemia. *Circulation* Supplement, 110: pp III-210
25. **September 7-10, 2004,** 25<sup>th</sup> Anniversary Workshop for ICBP-NS, Bucharest, Romania. Authors: **Kyriakos E. Kypreos** and VI Zannis. Title: Effects of an apoA-I variant on cholesterol and triglyceride homeostasis.
26. **September 2-5, 2004,** 1<sup>st</sup> HDL Workshop, Crete, Greece. Authors: **Kyriakos E. Kypreos** and VI Zannis. Title: Effects of apoE mutations on HDL levels and composition
27. **May 6-8, 2004.** 5<sup>th</sup> annual meeting of the council for Atherosclerosis, Thrombosis, and Vascular Biology, San Francisco, California, USA. Authors: G Gerritsen, PCN Rensen, **Kyriakos E. Kypreos**, SMS Espirito Santo, BJM van Vlijmen, LM Havekes, and K Willems van Dijk. Title: Hepatic LRP deficiency in LDL receptor and apoE deficient mice results in an increase in the peripheral VLDL-TG lipolysis rate
28. **November 19-21, 2003.** Evans Research Days, Department of Medicine, Boston University School of Medicine, Boston, MA., USA. Authors: Angeliki Chroni\*, **Kyriakos E. Kypreos\***, Horng-Yuan Kan\*, Irina Gorshkova, Adelina Shkodrani, and Vassilis I. Zannis. Title: Substitutions of Glu110, Glu111 in the middle helix 4 of apoA-I by Ala affect the structure and the in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I deficient mice
29. **November 19-21, 2003.** Evans Research Days, Department of Medicine, Boston University School of Medicine, Boston, MA., USA Authors: **Kyriakos E. Kypreos**, and Zannis V.I. Title: Residues L261, W264, F265, L268, V269 of apolipoprotein-E are responsible for the apoE-induced hypertriglyceridemia
30. **June 5-9, 2002.** 5<sup>th</sup> annual meeting of the American Society of Gene Therapy, 2, Boston, MA., USA Authors: Kan H-Y, **Kyriakos E. Kypreos**, and Vassilis I. Zannis. Title: Substitutions of Glu110, Glu111 in the middle helix 4 of apoA-I by Ala induces hypertriglyceridemia in ApoA-I<sup>-/-</sup> mice. Published in *Molecular Therapy* (2002) **5**: S235
31. **June, 2002.** 5<sup>th</sup> annual meeting of the American Society for Gene Therapy, Boston, MA., USA Authors: **Kyriakos E. Kypreos**, van Dijk K.W., Havekes, L., Zannis V.I. Title: "Use of Adenovirus-mediated gene transfer for the elucidation of the molecular mechanisms underlying type III hyperlipoproteinemia. Published in *Molecular Therapy* (2002) **5**: S235
32. **April, 2002.** 3<sup>rd</sup> annual meeting of the council for Atherosclerosis, Thrombosis, and Vascular Biology, Salt Lake City, Utah, USA Authors: **Kyriakos E. Kypreos**, van Dijk K.W., Havekes, L., Zannis V.I. Title: "Molecular mechanisms of type III hyperlipoproteinemia: the contribution of the carboxyterminal 203-299 domain of apoE2."

33. **May, 2001.** 23<sup>rd</sup> annual meeting of the Hellenic Society of Biological Sciences, Chios, Greece, EU. *Authors:* Zannis V.I., and **Kyriakos E. Kypreos**  
Title: "Role of apolipoprotein E in the development of atherosclerosis and Alzheimer disease: Gene therapy applications.
34. **November, 2001.** 74<sup>rd</sup> Annual Scientific Meeting of the American Heart Association, New Orleans, Louisiana, USA. *Authors:* **Kyriakos E. Kypreos**, Li X., van Dijk K.W., Havekes L.M., Zannis V.I. Title: "Apolipoprotein e2-202 corrects the high cholesterol profiles of apoe-deficient mice, and cholesterol clearance by full-length and truncated apoe forms is mediated by the LDL receptor".
35. **November, 2001.** 74<sup>rd</sup> Annual Scientific Meeting of the American Heart Association, New Orleans, Louisiana, USA. *Authors:* Gerritsen G., **Kyriakos E. Kypreos**, van der Zee A., Zannis V.I., Havekes L.M., van Dijk K.W. Title: "Hyperlipidemia in ApoE2 transgenic mice is aggravated by overexpression of full length apoE3 whereas it is reduced by a truncated apoE variant."
36. **November 14, 2000.** Annual "Evans Day" at Boston University, Boston, Massachusetts, USA. *Authors:* **Kyriakos E. Kypreos**, and Zannis, V. I. Title: "The Carboxyterminal 260-299 Domain of apoE Contributes to the apoE-Induced Hypertriglyceridemia *in vivo*." Published in *Circulation* (supplement)
37. **November 13, 2000.** 73<sup>rd</sup> Annual Scientific Meeting of the American Heart Association, New Orleans, Louisiana, USA. *Authors:* **Kyriakos E. Kypreos**, van Dijk, K. W., van der Zee, A., Havekes L. M., and Zannis, V. I. Title: "The Carboxyterminal 260-299 Domain of apoE Contributes to the apoE-Induced Hypertriglyceridemia *in vivo*." Published in *Circulation* (supplement)
38. **October 7, 2000.** 8<sup>th</sup> Annual meeting of the European society for Gene Therapy, Stockholm, Sweden, European Union. *Authors:* **Kyriakos E. Kypreos**, van Dijk, K. W., van der Zee, A., Havekes L. M., and Zannis, V. I. Title: "The Carboxyterminal 260-299 Domain of apoE Contributes to the apoE-Induced Hypertriglyceridemia *in vivo*."
39. **June 15, 2000.** 5<sup>th</sup> International Symposium on Atherosclerosis, Stockholm, Sweden, European Union. *Authors:* van Dijk, K. W., **Kyriakos E. Kypreos**, van der Zee, A., Havekes L. M., and Zannis, V. I. Title: "Domains of Apolipoprotein-E Contributing to Triglyceride and Cholesterol Homeostasis *in vivo*." *Oral presentation.*
40. **June 3, 2000.** 3<sup>th</sup> Annual Meeting of the "American Society of Gene Therapy", Denver, Colorado, U.S.A. *Authors:* **Kyriakos E. Kypreos**, van Dijk, K. W., van der Zee, A., Havekes L. M., and Zannis, V. I. Title: "The Carboxyterminal 203-299 Domain of apoE Contributes to the apoE-Induced Hypertriglyceridemia *in vivo*." *Oral Presentation.* Published in *Molecular Therapy*, (2000) 1, S256.
41. **May 21, 2000.** American Heart Association, 1<sup>st</sup> meeting on Atherosclerosis, Thrombosis and Vascular Biology, Denver, Colorado, U.S.A. *Authors:* **Kyriakos E. Kypreos**, van Dijk, K. W., van der Zee, A., Havekes L. M., and Zannis, V. I. Title: "Domains of Apolipoprotein-E Contributing to Triglyceride and Cholesterol Homeostasis *in vivo*." *Oral Presentation.*



## 21. CITATIONS, IMPACT FACTORS

For up to date information please visit my bio page on [www.kyriakoskypreos.com](http://www.kyriakoskypreos.com)

## 22. PRESENTATION OF MY WORK IN INTERNATIONAL WEBSITES

**Medwirenews, 17 November 2011.**

Reduced HDL apolipoprotein ratio linked to increased risk for heart attack in young: [http://m.medwire-news.md/40/95836/Lipidology/Reduced\\_HDL\\_apolipoprotein\\_ratio\\_linked\\_to\\_increased\\_risk\\_for\\_heart\\_attack\\_in\\_young](http://m.medwire-news.md/40/95836/Lipidology/Reduced_HDL_apolipoprotein_ratio_linked_to_increased_risk_for_heart_attack_in_young)

**MDLinx, February, 2011, *Most popular cardiology articles.***

Testosterone and Cardiovascular disease: an old idea with modern clinical implications, Atherosclerosis, February 22, 2011. (in the top 10 for February 2011): <http://www.mdlinx.com/cardiology/print.cfm/3485734/cardiovascular-diseases>

**Medwirenews, 19 December 2005.**

LDL receptor key to apoE-induced hypertriglyceridemia: <http://www.medwirenews.com/news/article.aspx?k=40&id=44904>

## **23. SOCIETIES - MEMBERSHIPS**

- 1. Hellenic Atherosclerosis Society. Member**
- 2. Hellenic Society of lipidology and arterial disease. Member**
- 3. European Association of Clinical and Laboratory Pharmacology and Therapeutics. Member**
- 4. Hellenic Pharmacological Society. Member**
- 5. European Atherosclerosis Society (EAS). Member**
- 6. American Heart Association (AHA). Associate Member**
- 7. European Society of Cardiology (ESC). Member**
- 8. American Physiological Society (APS). Associate Member**
- 9. American Society for Gene Therapy. Associate Member**
- 10. International Atherosclerosis Society. Member**